ClinicalTrials.gg
CompletedNCT02132117Updated Nov 18, 2019Results posted

Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

A Phase 3 interventional study of Oxymetazoline HCL Cream 1.0% and Vehicle to Oxymetazoline HCL Cream in Erythema and Rosacea, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
445
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Erythema with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Erythema · United States.

Enrollment
Largest of 52
445 · median 52
Started
2014
with 5 others
Phase 3
5 of 55
none open now
Registered
16th of 55
by date
Lead sponsor
7 of 55
Allergan

Among the 55 studies in Erythema with a site in United States, this one has the largest enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2014, is one of 5 in phase 3, and was the 16th registered.

Erythema

131 studies on the registry are indexed under Erythema; 17 are open to participants now.

Browse Erythema studies →

Open to participants now

8 of the 55 studies in Erythema with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Erythema studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Erythema with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

03

Conditions studied

  • Erythema
  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Moderate to severe persistent facial erythema associated with rosacea.

Exclusion criteria

Exclusion Criteria:

  • Greater than 3 inflammatory lesions on the face
  • Current treatment with monoamine oxidase (MAO) inhibitors
  • Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
445 participants (actual)

Study arms

  • Experimental
    Oxymetazoline HCL Cream 1.0%

    Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.

    Drug: Oxymetazoline HCL Cream 1.0%

  • Placebo comparator
    Vehicle

    Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.

    Drug: Vehicle to Oxymetazoline HCL Cream

Interventions

  • Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.

  • DrugVehicle to Oxymetazoline HCL Cream

    Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales

    The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29. Baseline was defined as the measurement at pre-dose on Day 1.

    Time frame: Baseline, Day 29 (Hours 3, 6, 9 and 12)

Secondary outcomes

  1. Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on SSA at Hours 3, 6, 9 and 12 on Day 29

    The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29.

    Time frame: Baseline, Day 29 (Hours 3, 6, 9 and 12)

  2. Percent Change From Baseline on Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA) at Hours 3, 6, 9 and 12 on Day 29

    DIA of photographs was used to assess rosacea facial redness and was defined as percentage of facial area occupied by redness. A higher value in the percentage of facial area occupied by facial redness indicated more redness. A negative/ lower number percent change from Baseline indicates improvement.

    Time frame: Baseline, Day 29 (Hours 3, 6, 9 and 12)

  3. Percentage of Participants Satisfied or Very Satisfied on Item #9 of Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR) at Hours 3, 6, 9 and 12 on Day 29

    Participants assessed their treatment satisfaction by answering Item #9 of the SAT-RFR: "Right now, how satisfied are you with the effect your study medication had on your facial redness?" using a 5-point scale where 0= very dissatisfied, 1=dissatisfied, 2=neither satisfied or dissatisfied, 3=satisfied, or 4=very satisfied. The percentage of participants who answered Satisfied or Very Satisfied is reported.

    Time frame: Day 29 (Hours 3, 6, 9 and 12)

  4. Change From Baseline on the Symptom Assessment for Rosacea Facial Redness (SA-RFR) Item # 4 at Hours 3, 6, 9 and 12 on Day 29

    Participants assessed the burning sensation associated with rosacea facial redness by answering Item #4 of the SA-RFR: "Right now, how much does your face burn because of your facial redness?" using a 5-point scale where 0=less severe to 4=severe. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Day 29 (Hours 3, 6, 9 and 12)

  5. Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1

    The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement.

    Time frame: Baseline, Day 1 (Hour 1)

07

Results

Posted Aug 2, 2016

Participant flow

Participant flow — Overall Study
MilestoneOxymetazoline HCL Cream 1.0%Vehicle
Started224221
Completed213216
Not completed115
Withdrew: Adverse event61
Withdrew: Lost to follow-up22
Withdrew: Personal reasons12
Withdrew: Other miscellaneous reasons20

Outcome measures

PrimaryPercentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales

The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29. Baseline was defined as the measurement at pre-dose on Day 1.

Time frame:
Baseline, Day 29 (Hours 3, 6, 9 and 12)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales
percentage of participantsOxymetazoline HCL Cream 1.0%Vehicle
Day 29 (Hour 3)14.37.4
Day 29 (Hour 6)13.44.8
Day 29 (Hour 9)15.58.5
Day 29 (Hour 12)12.36.1
SecondaryPercentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on SSA at Hours 3, 6, 9 and 12 on Day 29

The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on SSA from Baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) post-dose on Day 29.

Time frame:
Baseline, Day 29 (Hours 3, 6, 9 and 12)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on SSA at Hours 3, 6, 9 and 12 on Day 29
percentage of participantsOxymetazoline HCL Cream 1.0%Vehicle
Day 29 (Hour 3)24.115.8
Day 29 (Hour 6)24.814.7
Day 29 (Hour 9)22.016.0
Day 29 (Hour 12)23.715.8
SecondaryPercent Change From Baseline on Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA) at Hours 3, 6, 9 and 12 on Day 29

DIA of photographs was used to assess rosacea facial redness and was defined as percentage of facial area occupied by redness. A higher value in the percentage of facial area occupied by facial redness indicated more redness. A negative/ lower number percent change from Baseline indicates improvement.

Time frame:
Baseline, Day 29 (Hours 3, 6, 9 and 12)
Reported as:
Median · percent change in area of redness
Percent Change From Baseline on Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA) at Hours 3, 6, 9 and 12 on Day 29
percent change in area of rednessOxymetazoline HCL Cream 1.0%Vehicle
Day 29 (Hour 3)-25.70 ± 144.7760.00 ± 225.452
Day 29 (Hour 6)-15.95 ± 170.7352.25 ± 198.138
Day 29 (Hour 9)-10.95 ± 131.9335.15 ± 200.530
Day 29 (Hour 12)-9.60 ± 145.8981.00 ± 195.291
SecondaryPercentage of Participants Satisfied or Very Satisfied on Item #9 of Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR) at Hours 3, 6, 9 and 12 on Day 29

Participants assessed their treatment satisfaction by answering Item #9 of the SAT-RFR: "Right now, how satisfied are you with the effect your study medication had on your facial redness?" using a 5-point scale where 0= very dissatisfied, 1=dissatisfied, 2=neither satisfied or dissatisfied, 3=satisfied, or 4=very satisfied. The percentage of participants who answered Satisfied or Very Satisfied is reported.

Time frame:
Day 29 (Hours 3, 6, 9 and 12)
Reported as:
Number · percentage of participants
Percentage of Participants Satisfied or Very Satisfied on Item #9 of Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR) at Hours 3, 6, 9 and 12 on Day 29
percentage of participantsOxymetazoline HCL Cream 1.0%Vehicle
Day 29 (Hour 3)54.334.1
Day 29 (Hour 6)49.332.3
Day 29 (Hour 9)49.833.6
Day 29 (Hour 12)47.536.4
SecondaryChange From Baseline on the Symptom Assessment for Rosacea Facial Redness (SA-RFR) Item # 4 at Hours 3, 6, 9 and 12 on Day 29

Participants assessed the burning sensation associated with rosacea facial redness by answering Item #4 of the SA-RFR: "Right now, how much does your face burn because of your facial redness?" using a 5-point scale where 0=less severe to 4=severe. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Day 29 (Hours 3, 6, 9 and 12)
Reported as:
Mean · score on a scale
Change From Baseline on the Symptom Assessment for Rosacea Facial Redness (SA-RFR) Item # 4 at Hours 3, 6, 9 and 12 on Day 29
score on a scaleOxymetazoline HCL Cream 1.0%Vehicle
Day 29 (Hour 3)-1.8 ± 0.97-1.6 ± 0.93
Day 29 (Hour 6)-1.8 ± 0.93-1.6 ± 0.91
Day 29 (Hour 9)-1.8 ± 0.91-1.7 ± 0.96
Day 29 (Hour 12)-1.8 ± 0.92-1.7 ± 0.91
SecondaryPercentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1

The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement.

Time frame:
Baseline, Day 1 (Hour 1)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1
percentage of participantsOxymetazoline HCL Cream 1.0%Vehicle
Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 129.716.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxymetazoline HCL Cream 1.0%—3/223 (1.3%)0/223 (0%)
Vehicle—2/221 (0.9%)0/221 (0%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventOxymetazoline HCL Cream 1.0%Vehicle
GoitreEndocrine disorders0/2231/221
HyperparathyroidismEndocrine disorders0/2231/221
Clavicle fractureInjury, poisoning and procedural complications0/2231/221
ConcussionInjury, poisoning and procedural complications0/2231/221
Rib fractureInjury, poisoning and procedural complications0/2231/221
Spinal fractureInjury, poisoning and procedural complications0/2231/221
Traumatic liver injuryInjury, poisoning and procedural complications0/2231/221
PneumothoraxRespiratory, thoracic and mediastinal disorders0/2231/221
Road traffic accidentInjury, poisoning and procedural complications1/2230/221
OsteoarthritisMusculoskeletal and connective tissue disorders1/2230/221

Baseline characteristics

Age, Customized
Age, Customized(participants)Oxymetazoline HCL Cream 1.0%VehicleTotal
18-64 years198193391
>=65 years262854
Sex: Female, Male
Sex: Female, Male(Participants)Oxymetazoline HCL Cream 1.0%VehicleTotal
Female177173350
Male474895
08

Study locations

1 site
  • College Station, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Apr 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2014
First posted
May 7, 2014
Start
Jun 2014
Primary completionActual
Apr 2015
CompletionActual
May 2015
Results first posted
Aug 2, 2016
Last update
Nov 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02132117
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
May 7, 2014
Start date
Jun 2014
Primary completion
Apr 2015
Completion
May 2015
Results posted
Aug 2, 2016
Last update
Nov 18, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxymetazoline

Start the discussion